What regulatory changes are shaping the clinical data landscape?

ICH E6(R3) is transforming oversight expectations, mandating proactive, risk-based approaches grounded in critical-to-quality (CtQ) factors. The focus has shifted from generic data integrity concerns to ensuring data reliability and participant safety through smarter trial design and continuous oversight. In parallel, the FDA’s draft guidance on AI in regulatory submissions signals growing openness to algorithmic support in quality and decision-making. Together, these developments are catalyzing a new generation of RBQM – one that is not just enabled by AI but defined by it, turning regulatory guidance into daily operating practice.

What does successful RBQM look like in 2026?

Successful RBQM in 2026 isn’t just implemented, it’s operationalized. It integrates intelligent tools into routine trial execution, enabling cross-functional teams to detect, prioritize, and act on risk in real time. By combining study level analytics with site level action planning, sponsors move beyond issue detection to proactive resolution. Supported by consulting expertise, this ecosystem enables a live, traceable RBQM process fully aligned with ICH E6(R3)/E8(R1), from risk assessment to regulatory inspection readiness.

Can you tell us more about adaptive site monitoring?

Adaptive site monitoring is the operational backbone of RBQM. It enables sponsors and CROs to dynamically assess risk at the site level using multi-factor scoring factoring in central statistical anomalies, protocol deviations, operational KPIs, and more. SPOT, our site oversight engine, prioritizes sites based on objective evidence and explains the “why” behind every score. This empowers CRAs to direct their time where it matters most, enhancing quality, reducing costs, and documenting defensible monitoring decisions.

How important do you think automation will be for the future of clinical trial data?

Automation is no longer a nice to have, it’s essential. Manual review processes are overburdened by the scale and complexity of modern trials. AI powered automation, like deep learning for medical coding, doesn’t just reduce workload; it boosts consistency and regulatory confidence. With tools that deliver up to 99% coding accuracy and 75%-time savings, automation shifts human focus back to CtQ issues and oversight. It’s not about replacing judgment; it’s about reinforcing it with scalable intelligence.

What other advancements are we seeing in clinical trial data management?

Data management is evolving from data cleaning to data intelligence. With AI driven tools like Intelligent Query Detection, teams can pre-emptively surface discrepancies with 90%+ precision, removing the need for endless listings and manual checks. Beyond discrepancy detection, platforms like MSR centralize clinical and safety review, providing cross-domain visibility that transforms how data managers, safety teams, and medical reviewers collaborate. This leads to faster cycles, reduced errors, and inspection-ready traceability.

AI continues to be a hot topic. Are there any trends you are particularly excited about?

The future of AI in RBQM lies in unifying fragmented tools into a connected intelligence layer. Rather than isolated solutions, we’re building agentic AI that reasons across data, suggests next actions, and explains its logic, always with a human in the loop. It’s about enabling CRAs, ClinOps, and data managers to engage in natural language, receive proactive alerts, and trust AI as a collaborator, not just a tool.

What do you think the future holds for clinical trial data?

We’re entering a phase where oversight becomes predictive, not reactive. As data volumes grow and trial designs become more complex, success depends on how quickly and clearly teams can interpret signals. RBQM is no longer a concept, it’s the operating system for modern trials. The future belongs to platforms that integrate risk detection, site oversight, and regulatory evidence in one unified environment: delivering faster, safer, and more defensible trials.